The underdosing with iron isomaltoside observed in this study may have resulted from targeting an insufficient Hb level for proper anemia correction and administering 500 mg iron doses to patients with advanced IDA (having an Hb < 10 g/dL). This evidence concerns the gene GSTM1 and anemia.